FDA Approved: WIXELA INHUB — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Mylan's supplemental application for WIXELA INHUB, a generic inhaled corticosteroid/long-acting beta-agonist combination (fluticasone propionate an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• WIXELA INHUB (Fluticasone propionate and salmeterol)

Snippet

SUPPL AP for WIXELA INHUB (FLUTICASONE PROPIONATE AND SALMETEROL)